6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Treatment-Resistant Depression: new trials by email Literature Review of Treatment-Resistant Depression trials Research Report on Treatment-Resistant Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression Psilocybin - Treatment-Resistant Depression | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 40 | 2026-07-03 | 2026-08-21 |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin - Major Depressive Disorder, Depression | Phase 2 | Active not recruiting | University Health Network, Toronto | 92 | 2024-02-05 | 2026-07-09 |
| Does Psilocybin Require Psychedelic Effects to Treat Depression? Psilocybin 25 mg, Risperidone 1 MG, Placebo - Treatment-resistant Depression | Phase 2 | Completed | Centre for Addiction and Mental Health | 41 | 2023-07-01 | 2026-05-07 |
| A Trial of GH001 in Patients With Treatment-resistant Depression GH001, Placebo - Treatment-resistant Depression | Phase 2 | Completed | GH Research Ireland Limited | 81 | 2023-05-24 | 2025-05-31 |
| Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg - Treatment-Resistant Depression | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2023-03-13 | 2025-04-13 |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression Psilocybin, Nicotinamide - Treatment-resistant Depression | Phase 2 | Completed | Central Institute of Mental Health, Mannheim | 144 | 2021-06-10 | 2025-01-20 |
| Antidepressant Effects of TS-161 in Treatment-Resistant Depression Placebo, TS-161 - Major Depressive Disorder, Treatment-Resistant Depression | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 11 | 2021-06-10 | 2025-06-10 |
| Efficacy and Safety of TAK-653 in Treatment-Resistant Depression TAK-653, Placebo - Treatment-Resistant Depression | Phase 2 | Withdrawn | Millennium Pharmaceuticals, Inc. | 2018-02-15 | 2018-02-22 | |
| Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression ketamine, midazolam - Treatment-resistant Depression | Phase 2 | Completed | VA Office of Research and Development | 62 | 2015-04-01 | 2024-04-25 |
| Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population Ketamine, Placebo - Depressive Disorder,, Treatment-Resistant Depression | Phase 2 | Unknown | Paul J. Lamothe | 60 | 2013-09-01 | 2015-03-17 |
| Action of Ketamine in Treatment-Resistant Depression Ketamine, Midazolam - Treatment-resistant Depression | Phase 2 / Phase 3 | Completed | University of Ottawa | 46 | 2013-05-01 | 2018-06-26 |
Depressive Disorder, Treatment-Resistant (11) · Depression (5) · Depressive Disorder, Major (5) · Depressive Disorder (1) · Mental Disorders (1) · Mood Disorders (1)
Depressive Disorder (10) · Mental Disorders (10) · Mood Disorders (10) · Behavior (5) · Behavioral Symptoms (5)
Ketamine (3) · Psilocybin (3) · Midazolam (2) · Methoxydimethyltryptamines (1) · Niacinamide (1) · Risperidone (1)
Centre for Addiction and Mental Health (2) · Central Institute of Mental Health, Mannheim (1) · GH Research Ireland Limited (1) · Millennium Pharmaceuticals, Inc. (1) · National Institute of Mental Health (NIMH) (1) · Novartis Pharmaceuticals (1) · Paul J. Lamothe (1) · University Health Network, Toronto (1) · University of Ottawa (1) · VA Office of Research and Development (1)
Canada (4) · United States (3) · Germany (2) · Poland (2) · Spain (2) · Czechia (1) · Ireland (1) · Japan (1) · Mexico (1) · Netherlands (1)
Carlos A Zarate, M.D. (1) · David N Lopez-Garza, M.D. (1) · Ishrat Husain, MBBS, MD (1) · Joshua Rosenblat, MD, MSc (1) · M. Ishrat Husain, MBBS, MD (1) · Manuel Ruiz-Alvarez, M.D. (1) · Paul J Lamothe, M.D. (1) · Paulo R Shiroma, MD (1) · Pierre Blier, M.D, Ph.D (1)
PMID 30922101, PMID 32591498, PMID 32871534, PMID 34971723, PMID 35931041, PMID 41848690, PMID 41879760
2017 (1)